Diagnostic Products Corporation Releases NT-proBNP Assay Outside the US
November 07 2005 - 7:00AM
Business Wire
Diagnostic Products Corporation (NYSE:DP) announced today the
release outside the US of its assay for N-terminal prohormone brain
natriuretic peptide (NT-proBNP). NT-proBNP is a diagnostic marker
of congestive heart failure (CHF) and is a prognostic marker of CHF
and acute coronary syndromes (ACS). The assay has received CE
approval for sale in the EU and is available immediately on DPC's
IMMULITE(R) 2000 and IMMULITE(R) 2500 immunoassay systems. "We are
extremely pleased to offer our customers a new assay for NT-proBNP,
one of today's most important cardiac biomarkers," said Michael
Ziering, DPC CEO. "Labs using the IMMULITE 2500 can now return
15-minute results for NT-proBNP as well as for the other STAT
cardiac assays we offer--troponin I, CK-MB and myoglobin--without
splitting samples. The lab's productivity benefits by performing
STATs along with our extensive menu of routine, esoteric and
allergy immunoassays on the same system." More than 22 million
people worldwide are afflicted with heart failure. In the US, it is
the most costly cardiovascular disease and the only cardiovascular
condition whose prevalence continues to rise. The symptoms of CHF
resemble those of other conditions, making CHF difficult to
diagnose. NT-proBNP is helpful for differentiating CHF from other
conditions. B-type natriuretic peptide (BNP) is released from the
left ventricle when the heart cannot pump blood efficiently. It
improves cardiac function by dilating blood vessels and inducing
the loss of water and sodium to reduce the fluid burden on the
heart. When BNP is cleaved from the precursor molecule proBNP,
NT-proBNP is released. NT-proBNP and BNP levels offer similar
information but NT-proBNP has the advantage of greater stability in
patient samples. About Diagnostic Products Corporation Diagnostic
Products Corporation, founded in 1971, is a global leader dedicated
to immunodiagnostics. DPC's product menu includes over 75
immunoassays and more than 375 specific allergens and allergy
panels. In addition, DPC addresses the chemistry and laboratory
automation testing needs of its customers through partnerships with
manufacturers of chemistry systems and reagents. The combined
chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested.
DPC also designs and manufactures automated laboratory
instrumentation, which provides fast, accurate results while
reducing labor and reagent costs. DPC sells its products to
hospitals, clinics and laboratories in more than 100 countries.
Additional Company information can be found on DPC's website at
www.dpcweb.com. Except for the historical information contained
herein, this press release contains forward-looking statements that
involve risks and uncertainties that could cause actual results to
differ materially. These factors include governmental or other
action relating to the Company's Chinese affiliate; the rate of
customer demand for the Company's products; the Company's ability
to successfully market new and existing products; its dependence on
certain suppliers; domestic and foreign government regulation; its
ability to keep abreast of technological innovations and to
translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC
reports and filings.
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Diagnostic Products (New York Stock Exchange): 0 recent articles
More Diagnostic Products Corporation News Articles